LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
TLPH
Talphera, Inc.
There isn't enough reported data to score TLPH yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TLPH Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TLPH's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TLPH PE Valuation
TLPH has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TLPH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| -- | |
| Limited | |
| High |
Analysts expect TLPH's losses to shrink, with revenue holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TLPH on earnings quality, reporting a profit while its opponent remains loss making.
TLPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.24 | +$0.13 |
| Q2 2026 | -$0.30 | +$0.09 |
| Q1 2026 | -$0.34 | +$0.10 |
| Q4 2025 | -$0.40 | +$0.10 |
| Q3 2025 | -$0.37 | +$0.34 |
| Q2 2025 | -$0.39 | +$0.27 |
| Q1 2025 | -$0.44 | +$0.47 |
| Q4 2024 | -$0.50 | +$1.00 |
TLPH is still losing money, but far less than before: $0.24 per share over the past year, against $14.00 at its worst in early 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over TLPH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
TLPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $281K | +12% |
| Q3 2023 | $117K | -77% |
| Q2 2023 | $253K | -56% |
| Q4 2022 | $252K | +12500% |
| Q3 2022 | $507K | -73% |
| Q2 2022 | $570K | +29% |
| Q1 2022 | $442K | -14% |
| Q4 2021 | $2K | -100% |
TLPH's revenue has slid since its 2020 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -342200% | N/A |
| Q1 2025 | -10800% | N/A |
| Q4 2023 | -1524% | +1425 points |
| Q3 2023 | -2828% | -1520 points |
| Q2 2023 | -1569% | +813 points |
| Q4 2022 | -2950% | +405800 points |
| Q3 2022 | -1308% | -844 points |
| Q2 2022 | -2381% | -121 points |
TLPH's operating margin was −342200% last quarter, down 340631 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TLPH on cash generation, producing positive trailing cash flow while its opponent burns cash.
TLPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3M | -$524K |
| Q2 2026 | -$3.9M | -$976K |
| Q1 2026 | -$3.4M | +$70K |
| Q4 2025 | -$2.4M | -$182K |
| Q3 2025 | -$2.5M | +$426K |
| Q2 2025 | -$2.9M | +$1.7M |
| Q1 2025 | -$3.5M | -$587K |
| Q4 2024 | -$2.3M | +$1.7M |
TLPH has burned cash in almost every quarter: −$13M over the past year, against −$11M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TLPH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TLPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +17.1K shares |
| 1 year | +82% | +34.1M shares |
| 3 years | +592% | +64.6M shares |
| 5 years | +1234% | +69.9M shares |
| Available history | +1808% | +71.6M shares |
TLPH has 76M diluted shares, up 82% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TLPH Net Leverage
TLPH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TLPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.1 | Neutral |
| Stochastic | 5.7 | Oversold |
TLPH's weekly RSI is 46 (neutral) and its Stochastic is 6 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TLPH PE vs Healthcare Sector
| Metric | TLPH | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TLPH has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TLPH on trend strength, trading above more of its moving averages.
TLPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.08 | 4.6% below |
| 20 week MA | $1.19 | 13% below |
| 50 week MA | $1.03 | 0% above |
| 100 week MA | $0.85 | 21% above |
| 200 week MA | $0.91 | 13% above |
TLPH has slipped below its 8-, 20- and 50-week averages, though it's still 13% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TLPH on returns for 2026, with the stronger performance.
TLPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.8 | $25.4 | -43% |
| 2021 | $25.4 | $11.2 | -56% |
| 2022 | $11.2 | $2.07 | -82% |
| 2023 | $2.07 | $0.74 | -64% |
| 2024 | $0.74 | $0.53 | -28% |
| 2025 | $0.53 | $1.10 | +108% |
| 2026 YTD | $1.10 | $1.03 | -6.4% |
TLPH's yearly returns have swung widely, from +108% in 2025 to −82% in 2022. It's down 6.4% so far in 2026.